Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ian M Rosenthal"'
Autor:
Ian M Rosenthal, Ming Zhang, Kathy N Williams, Charles A Peloquin, Sandeep Tyagi, Andrew A Vernon, William R Bishai, Richard E Chaisson, Jacques H Grosset, Eric L Nuermberger
Publikováno v:
PLoS Medicine, Vol 4, Iss 12, p e344 (2007)
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we exa
Externí odkaz:
https://doaj.org/article/b9fa516ad9b1418093488e15f77366b4
Autor:
Sewon Kang, Ian M. Rosenthal, Garth A. James, Nancy Cheng, Emmanuel F. Mongodin, Alessandra Agostinho-Hunt, Manisha J. Loss, Sherry Leung, Anna L. Chien, Katherine G. Thompson
Background The ability of Cutibacterium acnes strains to form biofilms has been correlated with their virulence. Objective This study examined biofilm and skin microbiota in acne patients in order to understand their role in the development of acne l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f47982bdc7cb77abc30e67067f7725ae
Autor:
Anthony J. Rizzo, Xiufeng Zhong, Ian M. Rosenthal, John R. Barber, Silvia Aparicio Domingo, Sumit Rajpara, M. Valeria Canto-Soler, Alan K. Meeker, W. Robert Bell, Christopher M. Heaphy, Corinne E. Joshu, Charles G. Eberhart, Miguel Flores Bellver
Publikováno v:
Brain Pathol
We have identified a discrete, focal telomere DNA expansion phenotype in the photoreceptor cell layer of normal, non-neoplastic human retinas. This phenotype is similar to that observed in a subset of human cancers, including a large fraction of tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224adbedee992336dcd34353ec7a2ba2
https://pubmed.ncbi.nlm.nih.gov/29668072
https://pubmed.ncbi.nlm.nih.gov/29668072
A dermatofibrosarcoma protuberans-like tumor with COL1A1 copy number gain in the absence of t(17;22)
Autor:
Kishwer S. Nehal, Mark A. Dickson, Lu Wang, Klaus J. Busam, Ian M. Rosenthal, Travis J. Hollmann, Meera Hameed, Jad Saab
A 57-year-old woman presented with a 3-year history of a progressive firm plaque on the right cheek. Skin biopsies revealed a bland, storiform, spindle-cell proliferation involving the deep dermis and subcutaneous fat. By immunohistochemistry, the tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbcc342db3ee4842705bd14667d48848
https://europepmc.org/articles/PMC5539502/
https://europepmc.org/articles/PMC5539502/
Autor:
Ian M. Rosenthal, Eric L. Nuermberger, Charles A. Peloquin, Rokeya Tasneen, Ming Zhang, Khisimuzi Mdluli, Deepak V. Almeida, Jacques H. Grosset, Petros C. Karakousis
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:4331-4340
In previous experiments, replacing the 10-mg/kg of body weight daily dose of rifampin with 7.5 to 10 mg/kg of rifapentine in combinations containing isoniazid and pyrazinamide reduced the duration of treatment needed to cure tuberculosis in BALB/c mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fbb318d255f1e16aa04f3e77074eac3
https://doi.org/10.1128/aac.00912-12
https://doi.org/10.1128/aac.00912-12
Autor:
Sandeep Tyagi, Kathy N. Williams, Ian M. Rosenthal, William R. Bishai, Jacques H. Grosset, Eric L. Nuermberger, Charles A. Peloquin, Deepak V. Almeida
Publikováno v:
Antimicrobial Agents and Chemotherapy. 50:2621-2625
The creation of new chemotherapeutic regimens that permit shortening the duration of treatment is a major priority for antituberculosis drug development. In this study, we used the murine model of experimental tuberculosis therapy to determine whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602656f36af61dd4d47b669ba62e039e
https://doi.org/10.1128/aac.00451-06
https://doi.org/10.1128/aac.00451-06
Autor:
Ian M. Rosenthal, Sandeep Tyagi, Jacques H. Grosset, Kathy N. Williams, Eric L. Nuermberger, Charles A. Peloquin, William R. Bishai, Andrew Vernon
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 174:94-101
Rationale: Recent studies have demonstrated that intermittent administration of rifamycin-based regimens results in higher rates of tuberculosis relapse and treatment failure compared with daily therapy. Twice-weekly treatment with rifampin, isoniazi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342dccf849b05a24f00037c3a1a59115
https://doi.org/10.1164/rccm.200602-280oc
https://doi.org/10.1164/rccm.200602-280oc
Autor:
Tetsuyuki Yoshimatsu, Sandeep Tyagi, Ian M. Rosenthal, Kathy N. Williams, William R. Bishai, Jacques H. Grosset, Eric L. Nuermberger, N Lounis
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:2289-2293
The nitroimidazopyran PA-824 has potent in vitro activity against Mycobacterium tuberculosis , a narrow spectrum of activity limited primarily to the M. tuberculosis complex, and no demonstrable cross-resistance to a variety of antituberculosis drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1141b73f69d65488b826d7e421f47f2d
https://doi.org/10.1128/aac.49.6.2289-2293.2005
https://doi.org/10.1128/aac.49.6.2289-2293.2005
Autor:
Ian M. Rosenthal, Tetsuyuki Yoshimatsu, Kathy N. Williams, Richard E. Chaisson, Jacques H. Grosset, Richard J. O'Brien, William R. Bishai, Andrew Vernon, Eric L. Nuermberger, Sandeep Tyagi
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 170:1131-1134
In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd932c87a1b2be9235c5d5c59251f725
https://doi.org/10.1164/rccm.200407-885oc
https://doi.org/10.1164/rccm.200407-885oc
Autor:
Eric L. Nuermberger, Ian M. Rosenthal, Deepak V. Almeida, Kathy N. Williams, Sandeep Tyagi, Rokeya Tasneen, Jacques H. Grosset
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:1522-1524
PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b42fc71b74527f74c542542d23fb33
https://doi.org/10.1128/aac.00074-08
https://doi.org/10.1128/aac.00074-08